Cognizant partners with NVIDIA to boost drug discovery with AI

TEANECK, N.J. - Cognizant Technology Solutions Corp. (NASDAQ:CTSH) has announced a collaboration with NVIDIA Corporation (NASDAQ:NVDA) to enhance drug discovery in the life sciences sector using NVIDIA\'s BioNeMo generative AI platform. This initiative aims to improve the productivity of the drug development process and accelerate the introduction of new treatments to the market. Generative AI...

Read More

KeyBanc starts Atlassian stock with Sector Weight, eyes cloud transition impact

On Tuesday, KeyBanc initiated coverage on Atlassian (NASDAQ:TEAM) Corporation stock (NASDAQ:TEAM), assigning a Sector Weight rating. The firm highlighted Atlassian\'s strong position in the developer collaboration market, particularly with its Jira Software and Confluence products. KeyBanc sees a long-term growth opportunity for Atlassian as it transitions from data center (DC) to cloud-based services and expands...

Read More

Guggenheim starts DXC Technology stock, eyes management\'s turnaround effort

On Tuesday, Guggenheim initiated coverage on DXC Technology stock (NYSE: NYSE:DXC), assigning a Neutral rating. The firm\'s analysis pointed to the challenges faced by the new management team, which has taken over an organization experiencing secular declines. The report acknowledged the potential for improvement under the new leadership but noted that such turnarounds are typically...

Read More

Guggenheim starts Perficient stock with Neutral on valuation and strategy balance

Tuesday, Guggenheim initiated coverage on Perficient stock (NASDAQ:PRFT), a digital consultancy firm, with a Neutral rating and a price target of $65.00. The firm recognized the company\'s high-value consulting-led approach and potential for margin expansion as it shifts more work offshore. The analyst noted that while Perficient\'s strategy for margin growth through a mix-shift in...

Read More

AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase

By Yadarisa Shabong (Reuters) -AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The deal is AstraZeneca (NASDAQ:AZN)\'s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up...

Read More

Guggenheim Neutral on TaskUs stock, sets $13 target on growth strategy balance

On Tuesday, Guggenheim initiated coverage on TaskUs, Inc stock(NASDAQ:TASK) with a Neutral rating and a price target set at $13.00. The firm\'s analysis suggests that while TaskUs is positioned to return to year-over-year revenue growth, the current risk and reward dynamics are evenly balanced. The new coverage reflects an evaluation of TaskUs\'s potential to generate...

Read More